Key Developments: Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

172.00USD
22 Aug 2014
Price Change (% chg)

$-0.09 (-0.05%)
Prev Close
$172.09
Open
$171.68
Day's High
$173.24
Day's Low
$171.20
Volume
710,544
Avg. Vol
1,389,535
52-wk High
$185.00
52-wk Low
$72.77

Search Stocks

Latest Key Developments (Source: Significant Developments)

Illumina Inc announces strategic partnerships with AstraZeneca, Janssen and Sanofi to redefine companion diagnostics for oncology
Thursday, 21 Aug 2014 02:00am EDT 

Illumina Inc:Says that it has formed collaborative partnerships with pharmaceutical companies to develop a universal sequencing (NGS) based oncology test system.Says the system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine.Initial strategic partners include AstraZeneca, Janssen Biotech, Inc., and Sanofi.Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners' clinical trials, with the objectives of securing regulatory agency approvals and test commercialization.Says in parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm.Says together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for companion therapeutics.  Full Article

Illumina Inc and Cypher Genomics enter agreement to facilitate genomic biomarker discovery
Thursday, 24 Jul 2014 06:00am EDT 

Illumina Inc:Cypher Genomics Inc says a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials.Cypher Genomics and Illumina will jointly offer pharmaceutical companies, through Illumina's sales force, a solution including Illumina's sequencing technology, the NextBio platform for data analytics and storage, and Cypher Genomics' biomarker discovery service, called Coral.Cypher Genomics technology reduces the signal-to-noise in genomic information to uncover important biomarkers in sample sizes typical of early stage drug development studies.  Full Article

Illumina Inc raises FY 2014 guidance
Wednesday, 23 Jul 2014 04:05pm EDT 

Illumina Inc:Raises FY 2014 guidance to 25 to 26 pct revenue growth.Raises FY 2014 non-GAAP earnings per fully diluted share to $2.26 to $2.28.Reported revenue of $1.421 bln in fiscal 2013.FY 2014 revenue of $1.758 bln and EPS of $2.17 - Thomson Reuters I/B/E/S.  Full Article

Illumina Inc announces acquisition Myraqa
Wednesday, 16 Jul 2014 06:30am EDT 

Illumina Inc:Has acquired Myraqa, a regulatory and quality consulting firm specializing in IVDs, particularly companion diagnostics.Financial terms were not disclosed.  Full Article

Illumina Inc enters agreements with Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsried
Monday, 30 Jun 2014 03:00am EDT 

Illumina Inc:Enters into separate agreements with Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsried, under which they will use HiSeq 2500 and consumables from Illumina to develop and perform non-invasive prenatal testing (NIPT).Biomnis plans to make NIPT available in France, Genoma plans to perform NIPT services in Italy, and the Center for Human Genetics and Laboratory Diagnostics will offer NIPT in Germany.  Full Article

Illumina Inc launches VeriSeq PGS
Tuesday, 29 Apr 2014 06:30am EDT 

Illumina Inc:Launches VeriSeq(TM)PGS, a sequencing (NGS) solution developed for preimplantation genetic screening (PGS) of embryos using Illumina's NextSeq500 and MiSeq sequencing systems.Offering brings together Illumina 24sure array-based platform for PGS with Illumina's sequencing (NGS) technology to offer laboratories a more scalable PGS solution.  Full Article

Illumina files new patent infringement suit against Ariosa Diagnostics, Inc
Friday, 25 Apr 2014 04:05pm EDT 

Illumina Inc:Filed a new patent infringement suit against Ariosa Diagnostics, Inc. Illumina is seeking all available remedies, including injunctive relief.Says new suit, filed in the U.S. District Court for the Northern District of California, is based on Ariosa's infringement of U.S. Patent No. 7,955,794, entitled Multiplex Nucleic Acid Reactions.Suit targets Ariosa's Harmony Prenatal Test, including its use of digital analysis of selected regions (DANSR) that, among other things, enables simultaneous quantification of hundreds of DNA loci.  Full Article

Illumina Inc raises FY 2014 outlook
Tuesday, 22 Apr 2014 04:05pm EDT 

Illumina Inc:Increases FY 2014 projections to about 21 pct. to 23 pct. revenue growth and non-GAAP earnings per fully diluted share (EPS) of $2.10 to $2.15.Reported revenue of $1.421 bln in fiscal 2013.FY 2014 revenue estimate of $1.680 bln and EPS of $2.05 - Thomson Reuters I/B/E/S.  Full Article

WuXi PharmaTech Purchases Illumina HiSeq X Ten Sequencing System
Monday, 10 Mar 2014 06:30am EDT 

Illumina Inc:Says WuXi Genome Center has purchased Illumina HiSeq X Ten sequencing system.  Full Article

Science for Life Laboratory joins Illumina Genome Network
Monday, 24 Feb 2014 06:30am EST 

Illumina, Inc:Science for Life Laboratory (SciLifeLab) in Sweden has joined Illumina Genome Network (IGN).To provide researchers with broader access to Illumina's whole genome sequencing technology.  Full Article

Illumina shares up on higher sales of gene-sequencing products

- Life-science tool maker Illumina Inc reported a better-than-expected jump in quarterly revenue, helped by strong sales of its gene-sequencing products.

Search Stocks